American Society of Clinical Oncology (ASCO) Award

 

A medical oncology registrar, Dr. Greg Korpanty, working with Dr. Bryan Hennessy has just recently won a prestigious merit award from the American Society of Clinical Oncology (ASCO) that will be presented to him at the annual meeting of ASCO in June in Chicago. The award was given for a research project entitled ‘Loss of heterozygosity (LOH) as a measure of whole genome instability in ovarian cancer correlates with clinical outcomes’.
 
This research will also be highlighted by an expert discussant at the annual meeting in Chicago as one of the outstanding research abstracts submitted to ASCO this year.

Newest Member of ICORG’s GCO team: Myriam Estrabaut

Myriam is a scientist with an oncology clinical trials background who has worked as a coordinator at the Institute Claudius Regaud, Toulouse, France. This is a highly regarded cancer centre which is a big centre in an ICORG like network in France.

New ICORG Vice-Chair Dr Ray McDermott

New ICORG Vice-Chair Dr Ray McDermott, Consultant Medical Oncologist, AMNCH; ICORG/ECOG PI, has recently been elected unopposed as the new Vice Chair of ICORG. He began his four year term of office on 1st January 2009.

ICORG’s new Chair Dr Paul Browne

ICORG’s new Chair Dr Paul Browne, Consultant Haematologist, St James’s Hospital, took up his four year term of office on 1st January 2009.

We would like to welcome ICORG’s new Chair, Dr Paul Browne, Consultant Haematologist, St James’s Hospital, who takes up his four year term of office on 1st January 2009.

Newest Member of ICORG’s GCO team

The ICORG Pharmacovigilance Unit has recently expanded and is pleased to welcome Armelle Donohoe, PhV Consultant and Sandra Boldrin, PhV Associate.

Armelle has over ten years experience in pharmacovigilance, and Sandra has worked in the area for two years.

Sandra is now the third ICORG employee to successfully complete the EMEA’s EudraVigilance training programme.

For more information on the ICORG group structure click here

Update on availability of the experimental drug abiraterone

Update on availability of the experimental drug abiraterone for treatment of prostate cancer in Ireland

 

On July 22nd 2008, exciting positive Phase 1 results were published for a new drug abiraterone acetate (Cougar Biotechnology Inc.®)in prostate cancer patients with advanced disease.

Deadline for ESMO grant to enhance implementation and research of Palliative Care in Oncology

We would like to remind you that ESMO offers grants to enhance implementation and research of Palliative Care in oncology, as adequate Palliative Care is one of the cornerstones of oncology practice.

If you are interested or your have started a research on Palliative Care, please download the application form, complete and send it along with the requested documentation by 1 June 2008.